FT商学院

Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness

When a rash broke out on the hand of a patient taking part in the trial of a promising schizophrenia drug, clinical investigator Greg Mattingly began to fret that it might be an allergic reaction.

Instead, it turned out to be a mark of success: the patient, in his fifties, had landed his first job in more than a decade as a waiter, and the skin inflammation was a side effect not of the drug, but of washing dishes.

Securing a full-time job may seem unremarkable, but for most people living with schizophrenia, it can represent a triumph against the odds.

您已阅读4%(558字),剩余96%(14593字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×